We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Immunovia Ab (publ) | LSE:0G8X | London | Ordinary Share | SE0006091997 | IMMUNOVIA ORD SHS |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 191.40 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Surgical,med Instr,apparatus | 1.8M | -309.44M | -6.8328 | -0.02 | 6.79M |
From May 2022 to May 2024
LUND, Sweden, Aug. 11, 2022 /PRNewswire/ -- The California Department of Public Health has granted Immunovia, Inc., the American subsidiary of Immunovia AB (Nasdaq :IMMNOV) (Stockholm: IMMNOV), a Clinical and Public Health Laboratory license, allowing physicians in California to order the IMMray PanCan-d test for their patients.
"People at risk for pancreatic cancer need better tools for early detection. We are thrilled that this approval enables us to make IMMray PanCan-d available to clinicians in California who care for those at risk." says Jeff Borcherding, Chief Executive Officer of Immunovia, Inc.
For more information, please contact:
Philipp Mathieu
CEO and President
Email: philipp.mathieu@immunovia.com
Karin Almqvist Liwendahl
Chief Financial Officer
Email: karin.almqvist.liwendahl@immunovia.com
The information was submitted for publication on August 10, 2022, at 09:55 am CET.
About Immunovia
Immunovia AB is a diagnostic company with the vision to revolutionize blood-based diagnostics and increase survival rates for patients with cancer.
Our first product, IMMray™ PanCan-d is the only blood test currently available specifically for the early detection of pancreatic cancer. The test has unmatched clinical performance. Commercialization of IMMray™ PanCan-d started in August 2021 in the USA and IMMray™ PanCan-d is offered as a laboratory developed test (LDT) exclusively through Immunovia, Inc. For more information see: www.immunoviainc.com.
Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups globally to make this test available to all high-risk pancreatic cancer groups.
The USA, the first market in which IMMray™ PanCan-d is commercially available, is the world's largest market for the detection of pancreatic cancer with an estimated value of more than USD 4 billion annually.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/immunovia-ab/r/immunovia--inc--issued-clinical-and-public-health-laboratory-license-from-california-dept-of-public-,c3612734
The following files are available for download:
https://mb.cision.com/Main/13121/3612734/1613663.pdf | Press release (PDF) |
Copyright 2022 PR Newswire
1 Year Immunovia Ab (publ) Chart |
1 Month Immunovia Ab (publ) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
